Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TELA Bio, Inc.TELA · Entity 7381 | Chief Medical Officer | February 24, 2021 | February 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TELA Bio, Inc.
Report date February 24, 2021 · Filed February 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 90,887 |
Reported balance
After 2021-02-24 transaction · row 1
1 source rowRow 1 · 2021-02-24 · Grant · Acquired 12,000 · Balance 90,887 F1: These restricted stock units will vest in four equal annual installments beginning on February 24, 2022, subject to the Reporting Person's continuous service with the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.99 · Expires 2031-02-24 | Direct | 21,800 |
Reported balance
After 2021-02-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-24 · Grant · Acquired 21,800 · Balance 21,800 F2: The option vests 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units will vest in four equal annual installments beginning on February 24, 2022, subject to the Reporting Person's continuous service with the Issuer.
F2: The option vests 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2021 Filed Feb 26, 2021 17:27 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (right to buy) · Derivative | 21,800 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001192482-21-000190 · edgar.xml · derivative · entry 2 PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,800 Underlying: Common Stock · 21,800 shares Expires 2031-02-24 F2 · derivative.exercise_date: The option vests 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 17:27 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000190 · edgar.xml · nonDerivative · entry 1 PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,887 F1 · shares: These restricted stock units will vest in four equal annual installments beginning on February 24, 2022, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:50 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 12,931 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000423 · edgar.xml · derivative · entry 6 PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,931 Underlying: Series B Preferred Stock · 523 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:50 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 12,931 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000423 · edgar.xml · derivative · entry 5 PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series B Preferred Stock · 12,931 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:50 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 315,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000423 · edgar.xml · derivative · entry 4 PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:50 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries A Preferred Stock · Derivative | 197,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000423 · edgar.xml · derivative · entry 3 PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:50 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 12,760 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000423 · edgar.xml · nonDerivative · entry 2 PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:50 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 7,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000423 · edgar.xml · nonDerivative · entry 1 PERSENAIRE MAARTEN · CIK 0001207313 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · balance_after: Reflects 15,572 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.